Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.
The regional neuronal changes taking place in the early and late stages of antipsychotic treatment are still not well characterized in humans. In addition, it is not known whether these regional changes are predictive of or are correlated with treatment response. Using PET with 15O, we evaluated the time course of regional cerebral blood flow (rCBF) patterns generated by a first (haloperidol) and a second (olanzapine) generation antipsychotic drug in patients with schizophrenia during a 6-week treatment trial. Patients were initially scanned after withdrawal of all psychotropic medication (2 weeks), and then blindly randomized to treatment with haloperidol (n=12) or olanzapine (n=17) for a period of 6 weeks. Patients were scanned again after 1 and 6 weeks of treatment. All assessments, including scanning sessions, were obtained in a double-blind manner. As hypothesized, we observed rCBF changes that were common to both the drugs, implicating cortico-subcortical and limbic neuronal networks in antipsychotic action. In addition, in these regions, some patterns seen at weeks 1 and 6 were distinctive, indexing neuronal changes related to an early (ventral striatum, hippocampus) and consolidated (anterior cingulate/medial frontal cortex) stage of drug response. Finally, both after 1 and 6 weeks of treatment, we observed differential patterns of rCBF activation between good and poor responders. After 1 week of treatment, greater rCBF increase in the ventral striatum and greater decrease in the hippocampus were associated with good response.
Lahti
Adrienne C
AC
Department of Psychiatry, University of Alabama at Birmingham, Birmingham, AL 35294, USA. alahti@uab.edu
Weiler
Martin A
MA
Holcomb
Henry H
HH
Tamminga
Carol A
CA
Cropsey
Karen L
KL
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D001921:Brain / Q000098:blood supply / Q000000981:diagnostic imaging / Q000503:physiopathology*; D002560:Cerebrovascular Circulation / Q000502:physiology; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008032:Limbic System / Q000098:blood supply / Q000000981:diagnostic imaging / Q000503:physiopathology*; D008279:Magnetic Resonance Imaging; D008297:Male; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales; D011877:Radionuclide Imaging; D012039:Regional Blood Flow / Q000502:physiology; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine
Neuropsychopharmacology. 1999 May;20(5):403-12
10192821
Nat Rev Neurosci. 2006 Apr;7(4):268-77
16552413
Neuropsychopharmacology. 1997 Oct;17(4):230-40
9326747
Am J Psychiatry. 2006 Apr;163(4):600-10
16585434
Prog Neurobiol. 1994 Oct;44(2):163-96
7831476
Trends Cogn Sci. 2000 Jun;4(6):215-222
10827444
J Neurosci. 1983 Aug;3(8):1607-19
6135762
Neuroscience. 1992;46(2):315-28
1347406
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40
8799184
Neuropsychopharmacology. 2004 Jan;29(1):133-45
14583740
Synapse. 1996 Sep;24(1):12-8
9046072
Br J Psychiatry. 2005 Oct;187:366-71
16199797
Schizophr Bull. 1997;23(2):287-303
9165638
Psychiatry Res. 1997 Nov 28;76(1):51-61
9498309
Hippocampus. 2001;11(5):543-50
11732707
Eur J Pharmacol. 1997 Nov 5;338(2):R3-5
9456005
Schizophr Res. 2009 Jan;107(1):13-21
18930379
J Nucl Med. 1983 Sep;24(9):790-8
6604140
Neuropsychopharmacology. 2005 Dec;30(12):2283-9
16123775
Am J Psychiatry. 2004 Jun;161(6):985-95
15169686
Psychopharmacology (Berl). 1995 Nov;122(2):198-201
8848537
Neuroimage. 1996 Dec;4(3 Pt 1):223-35
9345513
Science. 1983 Sep 9;221(4615):1054-7
6136093
Arch Gen Psychiatry. 1992 Aug;49(8):624-9
1637252
Psychiatry Res. 2005 May 30;139(1):19-30
15950442
Schizophr Res. 2007 Aug;94(1-3):293-305
17574821
Synapse. 1995 Apr;19(4):264-93
7792721
Biol Psychiatry. 2003 Apr 1;53(7):601-8
12679238
Neuropsychopharmacology. 1996 Feb;14(2):105-110
8822533
Am J Psychiatry. 1996 Jan;153(1):41-9
8540590
Arch Gen Psychiatry. 2005 Apr;62(4):361-70
15809403
Br J Psychiatry. 2000 Nov;177:402-7
11059992
J Neurochem. 1990 May;54(5):1755-60
1969939
J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):106-10
11784835
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8104-9
10884434
Neuropsychopharmacology. 2008 May;33(6):1276-86
17687264
J Clin Psychiatry. 2001 Oct;62(10):757-71
11816864
Neurochem Int. 1998 Nov;33(5):383-97
9874089
Neuropsychopharmacology. 2004 Jan;29(1):171-8
14520337
Neuropsychopharmacology. 1998 Jul;19(1):36-47
9608575
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):253-8
12506194
Neuropsychopharmacology. 2006 Jan;31(1):221-30
16123774
Prog Brain Res. 1990;85:119-46
2094891
Arch Gen Psychiatry. 1992 Dec;49(12):966-74
1449383
Arch Gen Psychiatry. 2003 Dec;60(12):1228-35
14662555
Neuroimage. 1997 May;5(4 Pt 1):261-70
9345555